BR0209662A - Método para o tratamento e/ou profilaxia de condições caracterizadas pela função alterada de instestino e/ou dor visceral em seres humanos ou mamìferos não humanos - Google Patents

Método para o tratamento e/ou profilaxia de condições caracterizadas pela função alterada de instestino e/ou dor visceral em seres humanos ou mamìferos não humanos

Info

Publication number
BR0209662A
BR0209662A BR0209662-5A BR0209662A BR0209662A BR 0209662 A BR0209662 A BR 0209662A BR 0209662 A BR0209662 A BR 0209662A BR 0209662 A BR0209662 A BR 0209662A
Authority
BR
Brazil
Prior art keywords
treatment
functional
prophylaxis
visceral pain
humans
Prior art date
Application number
BR0209662-5A
Other languages
English (en)
Inventor
Douglas William Pierre Hay
Gareth John Sanger
Tadataka Yamada
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0112208A external-priority patent/GB0112208D0/en
Priority claimed from GB0129268A external-priority patent/GB0129268D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0209662A publication Critical patent/BR0209662A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODO PARA O TRATAMENTO E/OU PROFILAXIA DE CONDIçõES CARACTERIZADAS PELA FUNçãO ALTERADA DE INTESTINO E/OU DOR VISCERAL EM EM SERES HUMANOS OU MAMìFEROS NãO HUMANOS". Cujo método compreende a administração de uma quantidade eficaz, não tóxica e farmaceuticamente aceitável de um antagonista receptor de NK~ 3~, em que a condição caracterizada pela função alterada de intestino e/ou dor visceral é selecionada entre certas condições de síndrome de intestino irritável, distensão funcional abdominal, constipação funcional, diarréia funcional, outras condições de intestino e dor funcional abdominal.
BR0209662-5A 2001-05-18 2002-05-17 Método para o tratamento e/ou profilaxia de condições caracterizadas pela função alterada de instestino e/ou dor visceral em seres humanos ou mamìferos não humanos BR0209662A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0112208A GB0112208D0 (en) 2001-05-18 2001-05-18 New use
GB0129268A GB0129268D0 (en) 2001-12-06 2001-12-06 Novel use
PCT/US2002/015911 WO2002094187A2 (en) 2001-05-18 2002-05-17 Novel use

Publications (1)

Publication Number Publication Date
BR0209662A true BR0209662A (pt) 2004-04-20

Family

ID=26246093

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209662-5A BR0209662A (pt) 2001-05-18 2002-05-17 Método para o tratamento e/ou profilaxia de condições caracterizadas pela função alterada de instestino e/ou dor visceral em seres humanos ou mamìferos não humanos

Country Status (19)

Country Link
EP (1) EP1387687A4 (pt)
JP (1) JP2004534761A (pt)
KR (1) KR20040016865A (pt)
CN (1) CN1269483C (pt)
AR (1) AR045879A1 (pt)
AU (1) AU2002303811B2 (pt)
BR (1) BR0209662A (pt)
CA (1) CA2447063A1 (pt)
CZ (1) CZ20033115A3 (pt)
HU (1) HUP0400966A2 (pt)
IL (1) IL158701A0 (pt)
MX (1) MXPA03010509A (pt)
MY (1) MY134211A (pt)
NO (1) NO20035121L (pt)
NZ (1) NZ529462A (pt)
PE (1) PE20021067A1 (pt)
PL (1) PL367308A1 (pt)
TW (1) TWI243678B (pt)
WO (1) WO2002094187A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE477268T1 (de) 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PL1729734T3 (pl) * 2004-03-30 2008-09-30 Smithkline Beecham Corp Kompozycje farmaceutyczne suszone rozpyłowo
WO2005100997A2 (en) * 2004-04-16 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
US20080255193A1 (en) * 2005-09-30 2008-10-16 Jeffrey Brum Pharmaceutical Composition
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR20170091783A (ko) 2008-12-31 2017-08-09 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
KR200452372Y1 (ko) * 2010-05-14 2011-02-22 서일수 건설용 리프트의 통신선 지지장치
KR101034774B1 (ko) * 2010-07-30 2011-05-17 (주)챔피온코리아 와이어로프를 이용한 리프트 장치
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2013304812B2 (en) 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
SMT201900386T1 (it) 2013-04-12 2019-09-09 Ardelyx Inc Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato
WO2014170648A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬
AU2018205400C1 (en) 2017-01-09 2026-01-15 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
ES2201509T3 (es) * 1997-05-23 2004-03-16 Glaxosmithkline S.P.A. Derivados de quinolina-4-carboxamida como antagonista de los receptores nk-2 y nk-3.
CN1406225A (zh) * 1998-11-20 2003-03-26 葛兰素史密丝克莱恩有限公司 用作nk－3和nk－2受体拮抗剂的喹啉－4－甲酰胺衍生物

Also Published As

Publication number Publication date
PL367308A1 (en) 2005-02-21
TWI243678B (en) 2005-11-21
IL158701A0 (en) 2004-05-12
WO2002094187A3 (en) 2003-05-30
NO20035121D0 (no) 2003-11-17
PE20021067A1 (es) 2003-02-02
KR20040016865A (ko) 2004-02-25
AR045879A1 (es) 2005-11-16
WO2002094187A2 (en) 2002-11-28
CZ20033115A3 (cs) 2004-09-15
MXPA03010509A (es) 2004-03-02
CA2447063A1 (en) 2002-11-28
CN1269483C (zh) 2006-08-16
EP1387687A4 (en) 2006-07-05
JP2004534761A (ja) 2004-11-18
MY134211A (en) 2007-11-30
NZ529462A (en) 2005-07-29
NO20035121L (no) 2003-11-17
EP1387687A2 (en) 2004-02-11
AU2002303811B2 (en) 2005-07-07
HUP0400966A2 (hu) 2004-08-30
CN1509175A (zh) 2004-06-30

Similar Documents

Publication Publication Date Title
MY134211A (en) Novel use
UA89791C2 (ru) Пищевая композиция, которая содержит неусваиваемые олигосахариды, для лечения или профилактики инфекций респираторного тракта
EP0871488A4 (en) ANAL-SAFE SYNERGY THROUGH SIMULTANEOUS ADMINISTRATION OF SUBANAL-SIDED CANES FROM A MU OPIOID ANAGONIST AND A KAPPA - 2 OPIOID ANAGONIST
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
ATE383875T1 (de) Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
AU4063601A (en) Use of il-18 inhibitors
HU9603228D0 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
IL183565A0 (en) 5ht2c receptor modulator compositions and methods of use
PT1041987E (pt) Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
CA2505964A1 (en) Pharmaceutical compositions and dosage forms of thalidomide
AU2003243545A1 (en) Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
WO2001041748A3 (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
BR9916759A (pt) Processo para tratamento de distúrbios sexuais
BR9912508A (pt) Métodos e composições transdérmicas para alìvio da dor
KR930702000A (ko) 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
NZ334029A (en) Use of serotonin 5-HT1F agonist for the treatment of common colds or allergic rhinitis
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
SI1073456T1 (sl) Uporaba osteoprotegerina za preventivo pred kardiovaskularnimi boleznimi in za njihovo zdravljenje
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
BR0214643A (pt) Aplicação de um antagonista h1, e um esteróide seguro para tratar rinite
WO2006041800A3 (en) 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated kv1.3 potassium channel
EP1260221A3 (en) Combination treatment for depression and anxiety
ZA200405437B (en) Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for the prevention or treatment of pathogenic conditions.
NZ523676A (en) Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.